FMP

FMP

Enter

GLUE - Monte Rosa Therapeutics, Inc.

Profile of Monte Rosa Therapeutics, Inc.(GLUE), Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel smal

photo-url-https://financialmodelingprep.com/image-stock/GLUE.png

Monte Rosa Therapeutics, Inc.

GLUE

NASDAQ

7.04 USD

0.02 (0.284%)

About

ceo

Dr. Markus Warmuth M.D.

sector

Healthcare

industry

Biotechnology

website

https://www.monterosatx.com

exchange

NASDAQ

Description

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

CIK

0001826457

ISIN

US61225M1027

CUSIP

61225M102

Address

645 Summer Street

Phone

617 949 2643

Country

US

Employee

133

IPO Date

Jun 24, 2021

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep